Saturday, December 30, 2017

Biocon gets Brazilian regulatory approval

Bangalore based bio pharmaceutical enterprise Biocon has received approval for its proposed biosimilar 'trastuzumab' by Brazilian regulatory agency ANVISA, through their partner Libbs Farmaceutica.

Biocon has developed the drug along with  US based drug major Mylan. 

Biosimilar trastuzumab, indicated for breast cancer treatment.

2 comments:

  1. Hi FirstChoice IPO Analysis Team,

    My name is Anuj Agarwal. I'm Founder of Feedspot.

    I would like to personally congratulate you as your blog FirstChoice IPO Analysis has been selected by our panelist as one of the Top 20 IPO Blogs on the web.

    https://blog.feedspot.com/ipo_blogs/

    I personally give you a high-five and want to thank you for your contribution to this world. This is the most comprehensive list of Top 20 IPO Blogs on the internet and I’m honored to have you as part of this!

    Also, you have the honor of displaying the badge on your blog.

    Best,
    Anuj

    ReplyDelete